Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

L-161982

Copy Product Info
😃Good
Catalog No. T15681Cas No. 147776-06-5

L-161982 is a selective EP4 receptor antagonist that inhibits PGE2-induced ERK phosphorylation and cell proliferation in HCA-7 cells and alleviates collagen-induced arthritis in mice.

L-161982

L-161982

Copy Product Info
😃Good
Purity: 99.6%
Catalog No. T15681Cas No. 147776-06-5
L-161982 is a selective EP4 receptor antagonist that inhibits PGE2-induced ERK phosphorylation and cell proliferation in HCA-7 cells and alleviates collagen-induced arthritis in mice.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$64In StockIn Stock
5 mg$131In StockIn Stock
10 mg$223In StockIn Stock
25 mg$471In StockIn Stock
50 mg$676In StockIn Stock
100 mg$943In StockIn Stock
200 mg$1,270-In Stock
1 mL x 10 mM (in DMSO)$189In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.6%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
L-161982 is a selective EP4 receptor antagonist that inhibits PGE2-induced ERK phosphorylation and cell proliferation in HCA-7 cells and alleviates collagen-induced arthritis in mice.
In vitro
METHODS: HCA-7 cells were pre-incubated with L-161,982 (10 μM) and then stimulated with PGE for 72 h to evaluate whether inhibition of EP4 receptors by L-161,982 inhibits cell proliferation of PGE-stimulated HCA-7 cells.
RESULTS Pre-treatment with L-161,982 blocked PGE2-induced cell proliferation. [1]
METHODS: HCA-7 cells were pretreated with L-161982 (10 μM, 1 hour) and then stimulated with PGE2 for another 1 hour to investigate whether L-161982 would lead to inhibition of ERK activation as assessed by ERK phosphorylation status.
RESULTS ERK phosphorylation was completely blocked in HCA-7 cells pretreated with L-161982, indicating that L-161982 mediates PGE2-induced ERK phosphorylation in HCA-7 cells. [1]
METHODS: Tca8113 cells were stimulated with L-161982 (5, 10, 15, 20μM) for 24, 48 and 72 hours to study the effect of L-161982 on Tca8113 cell proliferation.
RESULTS The proliferation of Tca8113 cells was significantly reduced in a dose- and time-dependent manner; after 48 hours, IC50 was obtained at 15 μM; L-161982 inhibited the cell proliferation of Tca8113 cells in a dose- and time-dependent manner. [2]
In vivo
METHODS: The CIA mouse model was treated with L161982 (5 mg/kg, intraperitoneal injection, daily, 2 weeks) to evaluate the total arthritis score and histopathological examination to determine the severity of CIA; the plasma and tissue expressions of IL-17 and monocyte chemoattractant protein-1 (MCP-1) were detected by enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining (IHC), respectively; the proliferation of isolated Tregs and the Th17 polarization rate of naive T cells under L161982 treatment were tested by BrdU assay and flow cytometry, respectively.
RESULTS CIA mice treated with L161982 showed reduced arthritis scores, joint swelling, cracking of cartilage surface, and decreased hyperplasia in the connective tissue of the joint cavity. Plasma and tissue IL-17 and MCP-1 were reduced, while the proportion of Treg cells in the spleen and lymph nodes of CIA mice was increased. Otherwise, L161982 had no direct effect on the proliferation of Tregs; a reduced trend toward Th17 polarization in vitro was observed in L161982-treated naive T cells.[3]
Chemical Properties
Molecular Weight654.72
FormulaC32H29F3N4O4S2
Cas No.147776-06-5
SmilesO=C1N(N=C(CCCC)N1CC2=CC=C(C=C2)C3=C(S(NC(=O)C4=C(C)C=CS4)(=O)=O)C=CC=C3)C5=C(C(F)(F)F)C=CC=C5
Relative Density.1.37 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 150 mg/mL (229.11 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+90% Corn Oil: 0.5 mg/mL (0.76 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.5274 mL7.6369 mL15.2737 mL76.3685 mL
5 mM0.3055 mL1.5274 mL3.0547 mL15.2737 mL
10 mM0.1527 mL0.7637 mL1.5274 mL7.6369 mL
20 mM0.0764 mL0.3818 mL0.7637 mL3.8184 mL
50 mM0.0305 mL0.1527 mL0.3055 mL1.5274 mL
100 mM0.0153 mL0.0764 mL0.1527 mL0.7637 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy L-161982 | purchase L-161982 | L-161982 cost | order L-161982 | L-161982 chemical structure | L-161982 in vivo | L-161982 in vitro | L-161982 formula | L-161982 molecular weight